Key Points
- Director Josef Parvizi sold 25,000 shares on December 8 at an average price of $20.26, totaling $506,500, reducing his stake by 3.04% to 797,652 shares valued at about $16.16M.
- CeriBell shares were trading down roughly 4.9% around $20.18; the company remains loss-making despite beating recent revenue and EPS estimates, and analysts have a consensus "Moderate Buy" rating with an average target of $25.17.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca Robertson sold 5,000 shares of CeriBell stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the director directly owned 8,388 shares of the company's stock, valued at $167,760. This trade represents a 37.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
CeriBell Trading Down 4.4%
NASDAQ:CBLL opened at $20.29 on Thursday. The stock has a market cap of $752.76 million, a price-to-earnings ratio of -13.36 and a beta of 1.35. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The company's 50 day moving average price is $13.98 and its 200-day moving average price is $14.46. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The company had revenue of $22.59 million during the quarter, compared to analyst estimates of $21.78 million. On average, equities research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On CeriBell
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Deutsche Bank AG grew its position in CeriBell by 0.4% during the first quarter. Deutsche Bank AG now owns 231,629 shares of the company's stock valued at $4,450,000 after buying an additional 842 shares during the period. Swiss National Bank purchased a new position in shares of CeriBell during the 1st quarter worth $467,000. Nuveen LLC bought a new stake in shares of CeriBell during the 1st quarter valued at $311,000. Lord Abbett & CO. LLC increased its stake in shares of CeriBell by 7.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock worth $6,138,000 after purchasing an additional 23,451 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of CeriBell in the 1st quarter worth $175,000.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Raymond James Financial assumed coverage on CeriBell in a research report on Tuesday, October 21st. They set a "strong-buy" rating and a $19.00 price objective on the stock. Cowen restated a "buy" rating on shares of CeriBell in a research note on Tuesday. TD Cowen dropped their price target on shares of CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reissued a "sell (e+)" rating on shares of CeriBell in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.17.
Check Out Our Latest Stock Report on CBLL
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
